BridgeBio Pharma, Inc. — Director's Dealing 2021

Dec 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2021-12-03

Reporting Person: Kumar Neil (Director, CEO and President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-03	Stock Option (right to buy)	$38.62	A	786072	Acquired	2031-12-02	Common Stock (786072)	Direct

Footnotes

F1: The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.